Climb Bio Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Aoife Brennan
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 5.2% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$6m | US$330k | -US$74m |
Compensation vs Market: Aoife's total compensation ($USD6.34M) is above average for companies of similar size in the US market ($USD683.58K).
Compensation vs Earnings: Insufficient data to compare Aoife's compensation with company performance.
CEO
Aoife Brennan (47 yo)
less than a year
Tenure
US$6,335,702
Compensation
Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) and serves as its Director since June 2024. Dr. Brennan serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | no data | US$6.34m | no data | |
| COO, Treasurer | less than a year | US$3.32m | no data | |
| Senior VP of Finance & Chief Accounting Officer | 2.3yrs | no data | 0.022% $ 18.0k | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| VP & Head of Regulatory Affairs | no data | no data | no data | |
| Senior Vice President of Program Management | no data | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
0.8yrs
Average Tenure
47yo
Average Age
Experienced Management: CLYM's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$6.34m | no data | |
| Independent Director | 4.6yrs | US$118.62k | 0.26% $ 211.9k | |
| Independent Chairman of the Board | less than a year | US$98.39k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Director | no data | US$124.21k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Director | less than a year | US$1.73m | 0.27% $ 213.2k | |
| Independent Director | 4.3yrs | US$111.12k | 0% $ 0 |
0.9yrs
Average Tenure
53yo
Average Age
Experienced Board: CLYM's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 23:38 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Climb Bio, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Yatin Suneja | Guggenheim Securities, LLC |
| Marc Goodman | Leerink Partners LLC |